AgomAb Therapeutics (NASDAQ:AGMB) CEO Purchases 6,000 Shares of Stock

Key Points

• CEO Tim Jasper Knotnerus bought 6,000 AgomAb shares at an average price of $8.48, investing $50,880 and increasing his direct holdings by 55.44% to 16,823 shares. He also purchased an additional 5,000 shares the following day at $8.70 each.
• AgomAb shares opened at $8.84, near their 52-week low of $7.97 and well below the 52-week high of $17.82. The company reported a quarterly loss of $0.46 per share, while analysts expect a full-year loss of $1.76 per share.
• Analyst sentiment remains broadly positive, with seven Buy ratings and one Hold rating, producing a “Moderate Buy” consensus and a $37.50 average price target. AgomAb is a clinical-stage biotechnology company developing antibody-based treatments, including AGMB-129 for inflammatory bowel disease.

AgomAb Therapeutics NV (NASDAQ:AGMB - Get Free Report) CEO Tim Jasper Knotnerus purchased 6,000 shares of the firm's stock in a transaction dated Monday, October 5th. The shares were bought at an average cost of $8.48 per share, with a total value of $50,880.00. Following the purchase, the chief executive officer directly owned 16,823 shares of the company's stock, valued at approximately $142,659.04. This represents a 55.44% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Tim Jasper Knotnerus also recently made the following trade(s):

• On Tuesday, October 6th, Tim Jasper Knotnerus purchased 5,000 shares of AgomAb Therapeutics stock. The stock was purchased at an average price of $8.70 per share, with a total value of $43,500.00.

AgomAb Therapeutics Price Performance

Shares of NASDAQ:AGMB opened at $8.84 on Wednesday. The business's 50 day moving average is $12.82 and its 200 day moving average is $12.00. AgomAb Therapeutics NV has a 52-week low of $7.97 and a 52-week high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. On average, sell-side analysts forecast that AgomAb Therapeutics NV will post -1.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on AGMB. Cantor Fitzgerald initiated coverage on shares of AgomAb Therapeutics in a report on Wednesday, August 19th. They set an "overweight" rating on the stock. HC Wainwright reaffirmed a "buy" rating on shares of AgomAb Therapeutics in a research report on Wednesday, September 16th. B. Riley Financial started coverage on shares of AgomAb Therapeutics in a report on Thursday, July 23rd. They set a "buy" rating and a $34.00 price objective on the stock. Wall Street Zen downgraded shares of AgomAb Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, September 27th. Finally, Piper Sandler initiated coverage on AgomAb Therapeutics in a report on Tuesday, August 25th. They set an "overweight" rating and a $60.00 target price for the company. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $37.50.

AgomAb Therapeutics Company Profile

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab's lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.